Moderna Inc
NASDAQ:MRNA 4:00:00 PM EDT
| Market Cap (Intraday) | 11.10B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $27.22 |
| 50-Day MA | $26.50 |
| 200-Day MA | $39.18 |
Moderna Inc Stock, NASDAQ:MRNA
325 Binney Street, Cambridge, Massachusetts 02142
United States of America
Phone: +1.617.714.6500
Number of Employees: 5800
Description
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.